Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: LHC Group, Inc. (LHCG - Free Report) , Retrophin, Inc. (RTRX - Free Report) , Dermira, Inc. (DERM - Free Report) and Merck & Co., Inc. (MRK - Free Report) .

Here are highlights from Thursday’s Analyst Blog:

Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

The protracted United States and China trade war is unlikely to ease any time soon. In early October, deputy level officials from both countries had agreed to a “phase one” deal and strike off a tariff hike due in mid-October.

America’s move to halt the imposition of a fresh round of tariffs on Chinese products and China’s promise to buy more agricultural products from the United States brought about broad-based gains for the stock markets.

However, the phase one trade deal, which was to be signed at APEC Summit in Chile, got delayed after the summit got canceled.

The three major benchmarks — the Dow, S&P 500 and Nasdaq Composite — hit record highs on Nov 4 after investors got hopeful of a U.S.-China trade deal. In an interview with Bloomberg, U.S. Commerce Secretary Wilbur Ross had expressed optimism over a trade deal.

But on Nov 6, the Trump administration confirmed that the signing of the interim deal would potentially be pushed into December. Additionally, President Donald Trump’s administration official said “it was still possible the "phase one" agreement would not be reached, but a deal was more likely than not.” This has kept investors on tenterhooks as a trade deal seems far out of sight.

Such developments have weighed on the benchmark indexes lately. However, healthcare seems unperturbed by delays in a trade deal.

Should You Invest in Healthcare?

Healthcare stocks are considered as a defensive as they are need based and stay in constant demand just like utilities and consumer staples.

Investors often rely on the healthcare sector to safeguard their investments. This is because demand for healthcare services does not vary so much with market conditions and investments in the sector provide sufficient protection to the capital invested.

Many pharmaceutical companies also offer regular dividends. Companies that pay out consistent dividends are financially stable and generate consistent cash flows irrespective of market conditions.

The S&P 500 Health Care Sector index (XLV) has gained 10.6% on a year-to-date basis. Furthermore, a spate of healthcare mergers in the pipeline has also boosted the space. Bristol-Myers Squibb merged with Celgene in a $74 billion deal in January. Further, the $8 billion merger of Eli Lilly and Loxo Oncology in February also paved way for gains in healthcare.

This apart, the sector has also been on a hiring spree. Per the Institute for Supply Management’s (ISM) non-manufacturing index latest data, healthcare employment continued the northward movement in October also by adding 15,000 payrolls. Overall the health care sector has added 402,000 jobs in the past 12 months.

Notably, healthcare earnings have also remained largely unaffected by trade war woes. At a time when trade-sensitive sectors like tech have been battered by trade war woes, healthcare companies have raked in gains.

Companies like Humana, CVS Health Corp, DaVita have posted stellar third-quarter earnings and their shares have jumped 3.5%, 5.6% and 12.9%, respectively, since reporting earnings.

Our Top 4 Picks

U.S. healthcare has remained largely unaffected by trade related worries. Big names from the space have posted better-than-expected earnings over the last few quarters. Given such positives, investing in healthcare seems prudent. We have, thus, selected four stocks that should boost your portfolio. These stocks flaunt a Zacks Rank #1 (Strong Buy) or 2 (Buy).

LHC Group, Inc.is a publicly traded health care company that specializes in post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company’s expected earnings growth rate for the current year is 22.3%, which is above the Medical Services industry’s projected rally of 12.1%. The Zacks Consensus Estimate for current-year earnings has improved 0.5% over the past 90 days.

LHC Group flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Retrophin, Inc.is a publicly traded biopharmaceutical company that focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. The company’s expected earnings growth rate for the current year is 169.5%, which is above the Medical - Biomedical and Genetics industry’s projected rally of 6.4%.

The Zacks Consensus Estimate for current-year earnings has improved 14.4% over the past 60 days. Retrophin sports a Zacks Rank #1.

Dermira, Inc.is a publicly traded biopharmaceutical company that develops and commercializes therapies for patients with dermatologic diseases in the United States. The company’s expected earnings growth rate for the current quarter is 21.8%, which is above the Medical - Drugs industry’s decline of 107.4%.

The Zacks Consensus Estimate for current-year earnings has improved 14.4% over the past 60 days. Dermira carries a Zacks Rank #1.

Merck & Co., Inc.is a publicly traded biopharmaceutical company that focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. The company’s expected earnings growth rate for the current year is 16.6%, which is above the Large Cap Pharmaceuticals industry’s projected rally of 2.5%.

The Zacks Consensus Estimate for current-year earnings has improved 3.5% over the past 60 days. Merck & Co. carries a Zacks Rank #2.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

http://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Merck & Co., Inc. (MRK) - free report >>

Retrophin, Inc. (RTRX) - free report >>

Dermira, Inc. (DERM) - free report >>

LHC Group, Inc. (LHCG) - free report >>